-- Robert Preidt
THURSDAY, June 9 (HealthDay News) -- Some patients with advanced
cancer receive drugs that won't help them but could cause them
harm, a U.S. study suggests.
University of Chicago researchers analyzed medical and
pharmaceutical claims from 1,041 patients with metastatic colon
cancer who were treated between January 2007 and June 2010. Of
those patients, about one in eight received chemotherapy treatments
that weren't supported by evidence from clinical trials or by
clinical practice guidelines.
The researchers focused on three specific treatments. One had
insufficient data to support its use, one had been shown to be
ineffective, and one was not supported by data or a compelling
rationale, according to the study.
The treatment with insufficient data involved the use of Avastin
(bevacizumab) after a patient's cancer had progressed despite
treatment with a combination of the drug and chemotherapy. The
treatment shown to be ineffective was Xeloda (capecitabine) after
cancer progression while being treated with the same class of drug.
The treatment with no compelling rationale was Erbitux
(panitumumab/cetuximab) after cancer progression while being
treated with similar drugs.
The researchers said the patients who received these treatments
were exposed to significant risk without proven benefits at an
estimated cost of more than $2 million just for the drugs.
"Patients with advanced cancers that do no respond to standard therapies should either be looking for clinical trials, where there is a chance for benefit, or should have been thinking about shifting toward palliative care," study author Dr. Jonas De Souza, a hematology/oncology fellow, said in a university news release.
"Patients should not face the risks, discomforts and costs of aggressive and often quite toxic chemotherapy with treatment regimens that did not provide a benefit in previous studies," he added.
The study was presented this week at the American Society for
Clinical Oncology's annual meeting in Chicago. Experts note that
research presented at meetings should be considered preliminary
because it has not been subjected to the rigorous scrutiny given to
research published in medical journals.
The U.S. National Cancer Institute has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.